IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 265 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.49 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $68,175 | -74.1% | 10,669 | -32.3% | 0.00% | -100.0% |
| Q1 2022 | $263,000 | -69.2% | 15,768 | -41.6% | 0.00% | -50.0% |
| Q1 2021 | $855,000 | -40.5% | 27,017 | -12.7% | 0.00% | -33.3% |
| Q4 2020 | $1,437,000 | +166.6% | 30,965 | +89.2% | 0.00% | +200.0% |
| Q3 2020 | $539,000 | +19.8% | 16,368 | -0.2% | 0.00% | 0.0% |
| Q2 2020 | $450,000 | +11150.0% | 16,397 | +10831.3% | 0.00% | – |
| Q4 2019 | $4,000 | -99.5% | 150 | -99.7% | 0.00% | -100.0% |
| Q3 2019 | $809,000 | -90.4% | 44,427 | -87.0% | 0.00% | -90.0% |
| Q2 2019 | $8,408,000 | +210100.0% | 342,883 | +74117.1% | 0.02% | – |
| Q1 2019 | $4,000 | 0.0% | 462 | -8.5% | 0.00% | – |
| Q4 2018 | $4,000 | -98.9% | 505 | -98.4% | 0.00% | -100.0% |
| Q3 2018 | $360,000 | -68.7% | 32,000 | -64.4% | 0.00% | -66.7% |
| Q2 2018 | $1,151,000 | +2.8% | 89,911 | +35.7% | 0.00% | 0.0% |
| Q1 2018 | $1,120,000 | +27900.0% | 66,252 | +14209.3% | 0.00% | – |
| Q4 2017 | $4,000 | – | 463 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
| Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
| Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
| Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
| Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
| Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
| Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
| Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
| Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
| Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |